Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Roche launches cancer immunotherapy research network

Roche has launched a global cancer immunotherapy Centers of Research Excellence network, saying it will invest up to 100 million Swiss francs ($100.3 million) in the project.

Read More »

Heredity is not always destiny when it comes to heart attacks: study

If heredity puts you at higher risk for a heart attack, maintaining a healthy lifestyle can bring that risk down dramatically – below the risk faced by some people whose genes would normally protect them from heart disease – according to a new analysis of more than 55,000 people.

Read More »

Computer-brain interface helps locked-in patient communicate, albeit slowly

Doctors in the Netherlands say they have successfully tested an implantable computer-brain interface that allowed the mind of a “locked-in” patient to spell messages at the rate of two letters per minute.

Read More »

FDA rejects Dynavax’s hepatitis B vaccine

The U.S. Food and Drug Administration rejected Dynavax Technologies Corp.’s hepatitis B vaccine for the second time in three years.

Read More »

The Novartis house that Vasella built gets extreme makeover

Signals from Swiss drugmaker Novartis that it could unload its struggling Alcon eyecare business is the latest step in dismantling former leader Dan Vasella’s vision of building a European healthcare giant.

Read More »

Corbus drug succeeds in scleroderma study

Corbus Pharmaceuticals Holdings Inc. said its only drug outperformed a placebo in a mid-stage study involving patients with a form of systemic sclerosis.

Read More »

With Bristol-Myers Squibb, Genentech and Merck & Co. Expanding in the Bay Area, Some Wonder if the Real Estate Boom is Too Much

Biotech construction in the San Francisco Bay Area is booming, as it is in Boston. Merck may have a deal for 300,000 square feet in South San Francisco. Genentech, part of the Roche Group, acquired four buildings it had been leasing and is potentially acquiring four more.

Read More »

Celgene Exec Out as Trump Puts Vice President Elect Leader of Transition Effort

Celgene executive Rich Bagger will return to the private sector. That was the message President-elect Donald Trump’s transition team told the New York Times.

Read More »

Pfizer offers cut-price pneumonia shot for humanitarian crises

U.S. pharmaceuticals giant Pfizer is to offer its pneumococcal vaccine at the lowest possible price to non-governmental organizations seeking to protect vulnerable people from illness in humanitarian crises.

Read More »

Trump Promises to “Reform the FDA”

The President-Elect Donald Trump Administration has a new website and has updated – sort of – Trump’s intended policies for healthcare and biopharma.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom